OMIDRIA
Peakphenylephrine and ketorolac
NDAIRRIGATIONSOLUTION
Approved
May 2014
Lifecycle
Peak
Competitive Pressure
0/100
Data completeness
3/8 — Basic
OMIDRIA (phenylephrine and ketorolac) is cyclooxygenase inhibitors [moa]. First approved in 2014.
Drug data last refreshed 1h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
OMIDRIA is a fixed-dose combination of phenylephrine (alpha-1 agonist) and ketorolac (NSAID) delivered as an intraocular irrigation solution during cataract surgery. It maintains mydriasis (pupil dilation) and reduces inflammation intraoperatively, improving surgical conditions and postoperative outcomes. The product combines vasoconstrictive and anti-inflammatory mechanisms in a single ophthalmic formulation.
Peak7.8 years to LOE
Peak-stage specialty ophthalmic product with narrow market focus suggests smaller, focused commercial team relative to primary care therapeutics.
Mechanism of Action
Cyclooxygenase Inhibitors
Pharmacologic Class:
Nonsteroidal Anti-inflammatory Drug
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
OMIDRIA represents a specialized, mature surgical product requiring deep ophthalmic expertise and strong surgeon relationships rather than broad-based commercial scale. Roles on this brand emphasize consultative selling, clinical education, and niche market management rather than high-volume patient acquisition.
Brand Manager
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.